Cargando…
PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428988/ http://dx.doi.org/10.1097/01.HS9.0000851284.83380.89 |
| _version_ | 1784779292036562944 |
|---|---|
| author | Vitolo, U. Nowakowski, G. S. Burke, J. M. Fox, C. P. Trneny, M. Chiappella, A. Waldron-Lynch, M. Hadar, N. Pachori, A. Lenz, G. |
| author_facet | Vitolo, U. Nowakowski, G. S. Burke, J. M. Fox, C. P. Trneny, M. Chiappella, A. Waldron-Lynch, M. Hadar, N. Pachori, A. Lenz, G. |
| author_sort | Vitolo, U. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9428988 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94289882022-08-31 PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA Vitolo, U. Nowakowski, G. S. Burke, J. M. Fox, C. P. Trneny, M. Chiappella, A. Waldron-Lynch, M. Hadar, N. Pachori, A. Lenz, G. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9428988/ http://dx.doi.org/10.1097/01.HS9.0000851284.83380.89 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Vitolo, U. Nowakowski, G. S. Burke, J. M. Fox, C. P. Trneny, M. Chiappella, A. Waldron-Lynch, M. Hadar, N. Pachori, A. Lenz, G. PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title | PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full | PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title_fullStr | PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title_full_unstemmed | PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title_short | PB2113: FRONTMIND: A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF TAFASITAMAB + LENALIDOMIDE + R-CHOP VS R-CHOP ALONE FOR NEWLY DIAGNOSED HIGH-INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA |
| title_sort | pb2113: frontmind: a phase iii, randomized, double-blind study of tafasitamab + lenalidomide + r-chop vs r-chop alone for newly diagnosed high-intermediate and high-risk diffuse large b-cell lymphoma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428988/ http://dx.doi.org/10.1097/01.HS9.0000851284.83380.89 |
| work_keys_str_mv | AT vitolou pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT nowakowskigs pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT burkejm pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT foxcp pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT trnenym pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT chiappellaa pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT waldronlynchm pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT hadarn pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT pachoria pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma AT lenzg pb2113frontmindaphaseiiirandomizeddoubleblindstudyoftafasitamablenalidomiderchopvsrchopalonefornewlydiagnosedhighintermediateandhighriskdiffuselargebcelllymphoma |